Graybug Vision (NASDAQ:GRAY) Shares Down 0.4% – Should You Sell?

Graybug Vision, Inc. (NASDAQ:GRAYGet Free Report)’s share price was down 0.4% on Monday . The stock traded as low as $2.76 and last traded at $2.76. Approximately 68,617 shares traded hands during mid-day trading, an increase of 3,069% from the average daily volume of 2,165 shares. The stock had previously closed at $2.77.

Graybug Vision Price Performance

The firm has a market cap of $4.49 million, a PE ratio of -1.65 and a beta of 1.20. The business has a 50-day moving average price of $3.41 and a two-hundred day moving average price of $4.09.

Graybug Vision Company Profile

(Get Free Report)

Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.

Featured Stories

Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.